Causaly amplifies human cognitive abilities to expand the boundaries of discovery towards making the best decisions in Biomedicine.
To achieve this, we are teaching computers to read all knowledge ever published and develop an interface that allows humans to answer questions they can’t ask anywhere else.
To achieve this, we are teaching computers to read all knowledge ever published and develop an interface that allows humans to answer questions they can’t ask anywhere else.
Location: United Kingdom, England, London
Employees: 51-200
Total raised: $83M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 08.06.2021 | Index Vent... | indexventu... |
| - | Pentech Ve... | pentech.vc |
| - | Emerge Edu... | emerge.edu... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 13.07.2023 | Series B | $60M | - |
| 20.05.2021 | Series A | $17M | - |
| 20.11.2019 | Series A | $5M | Pentech Ve... |
| 26.07.2018 | Seed | $1M | - |
Mentions in press and media 24
| Date | Title | Description |
| 25.06.2025 | Causaly Launches AI-powered Competitive Intelligence App for Early-Stage Drug Discovery | What You Should Know: – Causaly today announced Pipeline Graph, giving pharma research and development teams a more effective and efficient way to do competitive intelligence earlier in drug discovery. – The AI-powered application lets scie... |
| 15.01.2025 | UK set for AI tech boost as millions of pounds injected after action plan | - |
| 18.12.2023 | The Largest Funding Rounds for Central and Eastern Europe in 2023 | Bulgaria, Czech Republic, Greece, Poland, Romania ~ Company: As the CEE region continues to establish itself as a key player in the global tech landscape, 2023 saw an influx of investment that has been pushing the development of regional st... |
| 22.08.2023 | Genesis Therapeutics Rakes In $200M For AI-Powered Drug Discovery | Several startups focused on AI-powered drug discovery have closed multi-million-dollar funding rounds this year, including Causaly, BenchSci, Iktos, TandemAI and Protai. Another one joined the list on Monday. Genesis Therapeutics announced ... |
| 31.07.2023 | 4 Ways Biopharma Is Applying AI/ML to Improve Drug Development Outcomes | Healthcare innovation in drug development intersects with a few critical trends: the rise of artificial intelligence (AI) applications in healthcare—particularly machine learning (ML) and predictive analytics; the need to reduce the costs a... |
| 13.07.2023 | Causaly, an AI platform for drug discovery and biomedical research, raises $60M | Artificial intelligence has been a big theme in the world of health and medical research, and specifically in the area of drug discovery. Today, another hopeful in the space is announcing a funding round to expand its own contribution to th... |
| 13.07.2023 | Causaly Secures $60M to Accelerate AI-Powered Biomedical Research | What You Should Know: Causaly, the leading AI platform for biomedical research raises $60M in Series B funding led by ICONIQ Growth, with participation from Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures and Visionaries Cl... |
| 13.07.2023 | Causaly Raises $60M in Series B Funding | Causaly, a London, UK- and Athens, Greece-based provider of an AI platform for biomedical research, raised $60M in Series B funding. The round, which brought the total amount to $93M, was led by ICONIQ Growth, with participation from Index ... |
| 13.07.2023 | Using AI for drug development, Causaly raises $60M | The company has now raised $93M in total Developing a new drug is a long process, typically taking over a decade, and it's expensive as well, often costing more than $2 billion. It can involve extensive research, development, and rigorous c... |
| 13.07.2023 | Greek ML Startup Causaly Raises $60M Series B to Advance Biomedical Research | Athens, Greece ~ Company: Only have 1 minute? Here are 3 takeaways from the piece: • Greek ML startup Causaly raised $60M Series B round led by Iconiq Growth together Index Ventures, Pentech, and EBRD among others • The company’s solution a... |
Show more